カテゴリー：世界, 医療/バイオ, QYResearch

がん向けバイオマーカー検査の世界市場インサイト・予測（～2028年）

【英語タイトル】Global Biomarker Testing for Cancer Market Insights, Forecast to 2028
	・商品コード：QY22JLX09341 ・発行会社（調査会社）：QYResearch ・発行日：2022年7月（※2025年版があります。お問い合わせください。）・ページ数：91 ・レポート言語：英語・レポート形式：PDF ・納品方法：Eメール（受注後3営業日）・調査対象地域：グローバル・産業分野：医療機器

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD4,900 ⇒換算￥744,800	見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）	USD7,350 ⇒換算￥1,117,200	見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）	USD9,800 ⇒換算￥1,489,600	見積依頼/購入/質問フォーム

※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）

❖ レポートの概要 ❖

COVID-19のパンデミックにより、がん向けバイオマーカー検査のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にがん向けバイオマーカー検査の世界市場のxxx％を占める「タンパク質バイオマーカー」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「診断薬」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
がん向けバイオマーカー検査の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのがん向けバイオマーカー検査市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

がん向けバイオマーカー検査のグローバル主要企業には、F. Hoffmann-L A Roche、Thermo Fisher Scientific、Qiagen N.V.、Bio-Rad L aboratories、lluminaなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

がん向けバイオマーカー検査市場は、種類と用途によって区分されます。世界のがん向けバイオマーカー検査市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
タンパク質バイオマーカー、遺伝子バイオマーカー、その他

【用途別セグメント】
診断薬、研究開発、診断薬、リスクアセスメント、その他

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- がん向けバイオマーカー検査製品概要
- 種類別市場（タンパク質バイオマーカー、遺伝子バイオマーカー、その他）
- 用途別市場（診断薬、研究開発、診断薬、リスクアセスメント、その他）
- 調査の目的
・エグゼクティブサマリー
- 世界のがん向けバイオマーカー検査販売量予測2017-2028
- 世界のがん向けバイオマーカー検査売上予測2017-2028
- がん向けバイオマーカー検査の地域別販売量
- がん向けバイオマーカー検査の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別がん向けバイオマーカー検査販売量
- 主要メーカー別がん向けバイオマーカー検査売上
- 主要メーカー別がん向けバイオマーカー検査価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（タンパク質バイオマーカー、遺伝子バイオマーカー、その他）
- がん向けバイオマーカー検査の種類別販売量
- がん向けバイオマーカー検査の種類別売上
- がん向けバイオマーカー検査の種類別価格
・用途別市場規模（診断薬、研究開発、診断薬、リスクアセスメント、その他）
- がん向けバイオマーカー検査の用途別販売量
- がん向けバイオマーカー検査の用途別売上
- がん向けバイオマーカー検査の用途別価格
・北米市場
- 北米のがん向けバイオマーカー検査市場規模（種類別、用途別）
- 主要国別のがん向けバイオマーカー検査市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパのがん向けバイオマーカー検査市場規模（種類別、用途別）
- 主要国別のがん向けバイオマーカー検査市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋のがん向けバイオマーカー検査市場規模（種類別、用途別）
- 主要国別のがん向けバイオマーカー検査市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米のがん向けバイオマーカー検査市場規模（種類別、用途別）
- 主要国別のがん向けバイオマーカー検査市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカのがん向けバイオマーカー検査市場規模（種類別、用途別）
- 主要国別のがん向けバイオマーカー検査市場規模（トルコ、サウジアラビア）
・企業情報
F. Hoffmann-L A Roche、Thermo Fisher Scientific、Qiagen N.V.、Bio-Rad L aboratories、llumina
・産業チェーン及び販売チャネル分析
- がん向けバイオマーカー検査の産業チェーン分析
- がん向けバイオマーカー検査の原材料
- がん向けバイオマーカー検査の生産プロセス
- がん向けバイオマーカー検査の販売及びマーケティング
- がん向けバイオマーカー検査の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- がん向けバイオマーカー検査の産業動向
- がん向けバイオマーカー検査のマーケットドライバー
- がん向けバイオマーカー検査の課題
- がん向けバイオマーカー検査の阻害要因
・主な調査結果

Cancer markers refer to substances directly produced by tumor cells or induced by non-tumor cells through tumor cells.
Market Analysis and Insights: Global Biomarker Testing for Cancer Market
Due to the COVID-19 pandemic, the global Biomarker Testing for Cancer market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Protein Biomarkers accounting for % of the Biomarker Testing for Cancer global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Diagnostics segment is altered to an % CAGR throughout this forecast period.
China Biomarker Testing for Cancer market size is valued at US$ million in 2021, while the US and Europe Biomarker Testing for Cancer are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Biomarker Testing for Cancer landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Biomarker Testing for Cancer include F. Hoffmann-L A Roche, Thermo Fisher Scientific, Qiagen N.V., Bio-Rad L aboratories and llumina, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Biomarker Testing for Cancer Scope and Segment
Biomarker Testing for Cancer market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Biomarker Testing for Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Protein Biomarkers
Genetic Biomarkers
Others
Segment by Application
Diagnostics
Research & Development
Prognostics
Risk Assessment
Others
By Company
F. Hoffmann-L A Roche
Thermo Fisher Scientific
Qiagen N.V.
Bio-Rad L aboratories
llumina
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

❖ レポートの目次 ❖

1 Study Coverage
1.1 Biomarker Testing for Cancer Product Introduction
1.2 Market by Type
1.2.1 Global Biomarker Testing for Cancer Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Protein Biomarkers
1.2.3 Genetic Biomarkers
1.2.4 Others
1.3 Market by Application
1.3.1 Global Biomarker Testing for Cancer Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Diagnostics
1.3.3 Research & Development
1.3.4 Prognostics
1.3.5 Risk Assessment
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Biomarker Testing for Cancer Sales Estimates and Forecasts 2017-2028
2.2 Global Biomarker Testing for Cancer Revenue Estimates and Forecasts 2017-2028
2.3 Global Biomarker Testing for Cancer Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Biomarker Testing for Cancer Sales by Region
2.4.1 Global Biomarker Testing for Cancer Sales by Region (2017-2022)
2.4.2 Global Sales Biomarker Testing for Cancer by Region (2023-2028)
2.5 Global Biomarker Testing for Cancer Revenue by Region
2.5.1 Global Biomarker Testing for Cancer Revenue by Region (2017-2022)
2.5.2 Global Biomarker Testing for Cancer Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Biomarker Testing for Cancer Sales by Manufacturers
3.1.1 Global Top Biomarker Testing for Cancer Manufacturers by Sales (2017-2022)
3.1.2 Global Biomarker Testing for Cancer Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Biomarker Testing for Cancer in 2021
3.2 Global Biomarker Testing for Cancer Revenue by Manufacturers
3.2.1 Global Biomarker Testing for Cancer Revenue by Manufacturers (2017-2022)
3.2.2 Global Biomarker Testing for Cancer Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Biomarker Testing for Cancer Revenue in 2021
3.3 Global Biomarker Testing for Cancer Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Biomarker Testing for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Biomarker Testing for Cancer Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Biomarker Testing for Cancer Sales by Type
4.1.1 Global Biomarker Testing for Cancer Historical Sales by Type (2017-2022)
4.1.2 Global Biomarker Testing for Cancer Forecasted Sales by Type (2023-2028)
4.1.3 Global Biomarker Testing for Cancer Sales Market Share by Type (2017-2028)
4.2 Global Biomarker Testing for Cancer Revenue by Type
4.2.1 Global Biomarker Testing for Cancer Historical Revenue by Type (2017-2022)
4.2.2 Global Biomarker Testing for Cancer Forecasted Revenue by Type (2023-2028)
4.2.3 Global Biomarker Testing for Cancer Revenue Market Share by Type (2017-2028)
4.3 Global Biomarker Testing for Cancer Price by Type
4.3.1 Global Biomarker Testing for Cancer Price by Type (2017-2022)
4.3.2 Global Biomarker Testing for Cancer Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Biomarker Testing for Cancer Sales by Application
5.1.1 Global Biomarker Testing for Cancer Historical Sales by Application (2017-2022)
5.1.2 Global Biomarker Testing for Cancer Forecasted Sales by Application (2023-2028)
5.1.3 Global Biomarker Testing for Cancer Sales Market Share by Application (2017-2028)
5.2 Global Biomarker Testing for Cancer Revenue by Application
5.2.1 Global Biomarker Testing for Cancer Historical Revenue by Application (2017-2022)
5.2.2 Global Biomarker Testing for Cancer Forecasted Revenue by Application (2023-2028)
5.2.3 Global Biomarker Testing for Cancer Revenue Market Share by Application (2017-2028)
5.3 Global Biomarker Testing for Cancer Price by Application
5.3.1 Global Biomarker Testing for Cancer Price by Application (2017-2022)
5.3.2 Global Biomarker Testing for Cancer Price Forecast by Application (2023-2028)
6 North America
6.1 North America Biomarker Testing for Cancer Market Size by Type
6.1.1 North America Biomarker Testing for Cancer Sales by Type (2017-2028)
6.1.2 North America Biomarker Testing for Cancer Revenue by Type (2017-2028)
6.2 North America Biomarker Testing for Cancer Market Size by Application
6.2.1 North America Biomarker Testing for Cancer Sales by Application (2017-2028)
6.2.2 North America Biomarker Testing for Cancer Revenue by Application (2017-2028)
6.3 North America Biomarker Testing for Cancer Market Size by Country
6.3.1 North America Biomarker Testing for Cancer Sales by Country (2017-2028)
6.3.2 North America Biomarker Testing for Cancer Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Biomarker Testing for Cancer Market Size by Type
7.1.1 Europe Biomarker Testing for Cancer Sales by Type (2017-2028)
7.1.2 Europe Biomarker Testing for Cancer Revenue by Type (2017-2028)
7.2 Europe Biomarker Testing for Cancer Market Size by Application
7.2.1 Europe Biomarker Testing for Cancer Sales by Application (2017-2028)
7.2.2 Europe Biomarker Testing for Cancer Revenue by Application (2017-2028)
7.3 Europe Biomarker Testing for Cancer Market Size by Country
7.3.1 Europe Biomarker Testing for Cancer Sales by Country (2017-2028)
7.3.2 Europe Biomarker Testing for Cancer Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Biomarker Testing for Cancer Market Size by Type
8.1.1 Asia Pacific Biomarker Testing for Cancer Sales by Type (2017-2028)
8.1.2 Asia Pacific Biomarker Testing for Cancer Revenue by Type (2017-2028)
8.2 Asia Pacific Biomarker Testing for Cancer Market Size by Application
8.2.1 Asia Pacific Biomarker Testing for Cancer Sales by Application (2017-2028)
8.2.2 Asia Pacific Biomarker Testing for Cancer Revenue by Application (2017-2028)
8.3 Asia Pacific Biomarker Testing for Cancer Market Size by Region
8.3.1 Asia Pacific Biomarker Testing for Cancer Sales by Region (2017-2028)
8.3.2 Asia Pacific Biomarker Testing for Cancer Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Biomarker Testing for Cancer Market Size by Type
9.1.1 Latin America Biomarker Testing for Cancer Sales by Type (2017-2028)
9.1.2 Latin America Biomarker Testing for Cancer Revenue by Type (2017-2028)
9.2 Latin America Biomarker Testing for Cancer Market Size by Application
9.2.1 Latin America Biomarker Testing for Cancer Sales by Application (2017-2028)
9.2.2 Latin America Biomarker Testing for Cancer Revenue by Application (2017-2028)
9.3 Latin America Biomarker Testing for Cancer Market Size by Country
9.3.1 Latin America Biomarker Testing for Cancer Sales by Country (2017-2028)
9.3.2 Latin America Biomarker Testing for Cancer Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Biomarker Testing for Cancer Market Size by Type
10.1.1 Middle East and Africa Biomarker Testing for Cancer Sales by Type (2017-2028)
10.1.2 Middle East and Africa Biomarker Testing for Cancer Revenue by Type (2017-2028)
10.2 Middle East and Africa Biomarker Testing for Cancer Market Size by Application
10.2.1 Middle East and Africa Biomarker Testing for Cancer Sales by Application (2017-2028)
10.2.2 Middle East and Africa Biomarker Testing for Cancer Revenue by Application (2017-2028)
10.3 Middle East and Africa Biomarker Testing for Cancer Market Size by Country
10.3.1 Middle East and Africa Biomarker Testing for Cancer Sales by Country (2017-2028)
10.3.2 Middle East and Africa Biomarker Testing for Cancer Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 F. Hoffmann-L A Roche
11.1.1 F. Hoffmann-L A Roche Corporation Information
11.1.2 F. Hoffmann-L A Roche Overview
11.1.3 F. Hoffmann-L A Roche Biomarker Testing for Cancer Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 F. Hoffmann-L A Roche Biomarker Testing for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 F. Hoffmann-L A Roche Recent Developments
11.2 Thermo Fisher Scientific
11.2.1 Thermo Fisher Scientific Corporation Information
11.2.2 Thermo Fisher Scientific Overview
11.2.3 Thermo Fisher Scientific Biomarker Testing for Cancer Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Thermo Fisher Scientific Biomarker Testing for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Thermo Fisher Scientific Recent Developments
11.3 Qiagen N.V.
11.3.1 Qiagen N.V. Corporation Information
11.3.2 Qiagen N.V. Overview
11.3.3 Qiagen N.V. Biomarker Testing for Cancer Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Qiagen N.V. Biomarker Testing for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Qiagen N.V. Recent Developments
11.4 Bio-Rad L aboratories
11.4.1 Bio-Rad L aboratories Corporation Information
11.4.2 Bio-Rad L aboratories Overview
11.4.3 Bio-Rad L aboratories Biomarker Testing for Cancer Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Bio-Rad L aboratories Biomarker Testing for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Bio-Rad L aboratories Recent Developments
11.5 llumina
11.5.1 llumina Corporation Information
11.5.2 llumina Overview
11.5.3 llumina Biomarker Testing for Cancer Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 llumina Biomarker Testing for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 llumina Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Biomarker Testing for Cancer Industry Chain Analysis
12.2 Biomarker Testing for Cancer Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Biomarker Testing for Cancer Production Mode & Process
12.4 Biomarker Testing for Cancer Sales and Marketing
12.4.1 Biomarker Testing for Cancer Sales Channels
12.4.2 Biomarker Testing for Cancer Distributors
12.5 Biomarker Testing for Cancer Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Biomarker Testing for Cancer Industry Trends
13.2 Biomarker Testing for Cancer Market Drivers
13.3 Biomarker Testing for Cancer Market Challenges
13.4 Biomarker Testing for Cancer Market Restraints
14 Key Findings in The Global Biomarker Testing for Cancer Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Biomarker Testing for Cancer Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Protein Biomarkers
Table 3. Major Manufacturers of Genetic Biomarkers
Table 4. Major Manufacturers of Others
Table 5. Global Biomarker Testing for Cancer Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Biomarker Testing for Cancer Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Biomarker Testing for Cancer Sales by Region (2017-2022) & (K Units)
Table 8. Global Biomarker Testing for Cancer Sales Market Share by Region (2017-2022)
Table 9. Global Biomarker Testing for Cancer Sales by Region (2023-2028) & (K Units)
Table 10. Global Biomarker Testing for Cancer Sales Market Share by Region (2023-2028)
Table 11. Global Biomarker Testing for Cancer Revenue by Region (2017-2022) & (US$ Million)
Table 12. Global Biomarker Testing for Cancer Revenue Market Share by Region (2017-2022)
Table 13. Global Biomarker Testing for Cancer Revenue by Region (2023-2028) & (US$ Million)
Table 14. Global Biomarker Testing for Cancer Revenue Market Share by Region (2023-2028)
Table 15. Global Biomarker Testing for Cancer Sales by Manufacturers (2017-2022) & (K Units)
Table 16. Global Biomarker Testing for Cancer Sales Share by Manufacturers (2017-2022)
Table 17. Global Biomarker Testing for Cancer Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 18. Global Biomarker Testing for Cancer Revenue Share by Manufacturers (2017-2022)
Table 19. Biomarker Testing for Cancer Price by Manufacturers (2017-2022) &(US$/Unit)
Table 20. Global Biomarker Testing for Cancer Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global Biomarker Testing for Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biomarker Testing for Cancer as of 2021)
Table 22. Biomarker Testing for Cancer Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Biomarker Testing for Cancer Product Offered
Table 24. Date of Manufacturers Enter into Biomarker Testing for Cancer Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Biomarker Testing for Cancer Sales by Type (2017-2022) & (K Units)
Table 27. Global Biomarker Testing for Cancer Sales by Type (2023-2028) & (K Units)
Table 28. Global Biomarker Testing for Cancer Sales Share by Type (2017-2022)
Table 29. Global Biomarker Testing for Cancer Sales Share by Type (2023-2028)
Table 30. Global Biomarker Testing for Cancer Revenue by Type (2017-2022) & (US$ Million)
Table 31. Global Biomarker Testing for Cancer Revenue by Type (2023-2028) & (US$ Million)
Table 32. Global Biomarker Testing for Cancer Revenue Share by Type (2017-2022)
Table 33. Global Biomarker Testing for Cancer Revenue Share by Type (2023-2028)
Table 34. Biomarker Testing for Cancer Price by Type (2017-2022) & (US$/Unit)
Table 35. Global Biomarker Testing for Cancer Price Forecast by Type (2023-2028) & (US$/Unit)
Table 36. Global Biomarker Testing for Cancer Sales by Application (2017-2022) & (K Units)
Table 37. Global Biomarker Testing for Cancer Sales by Application (2023-2028) & (K Units)
Table 38. Global Biomarker Testing for Cancer Sales Share by Application (2017-2022)
Table 39. Global Biomarker Testing for Cancer Sales Share by Application (2023-2028)
Table 40. Global Biomarker Testing for Cancer Revenue by Application (2017-2022) & (US$ Million)
Table 41. Global Biomarker Testing for Cancer Revenue by Application (2023-2028) & (US$ Million)
Table 42. Global Biomarker Testing for Cancer Revenue Share by Application (2017-2022)
Table 43. Global Biomarker Testing for Cancer Revenue Share by Application (2023-2028)
Table 44. Biomarker Testing for Cancer Price by Application (2017-2022) & (US$/Unit)
Table 45. Global Biomarker Testing for Cancer Price Forecast by Application (2023-2028) & (US$/Unit)
Table 46. North America Biomarker Testing for Cancer Sales by Type (2017-2022) & (K Units)
Table 47. North America Biomarker Testing for Cancer Sales by Type (2023-2028) & (K Units)
Table 48. North America Biomarker Testing for Cancer Revenue by Type (2017-2022) & (US$ Million)
Table 49. North America Biomarker Testing for Cancer Revenue by Type (2023-2028) & (US$ Million)
Table 50. North America Biomarker Testing for Cancer Sales by Application (2017-2022) & (K Units)
Table 51. North America Biomarker Testing for Cancer Sales by Application (2023-2028) & (K Units)
Table 52. North America Biomarker Testing for Cancer Revenue by Application (2017-2022) & (US$ Million)
Table 53. North America Biomarker Testing for Cancer Revenue by Application (2023-2028) & (US$ Million)
Table 54. North America Biomarker Testing for Cancer Sales by Country (2017-2022) & (K Units)
Table 55. North America Biomarker Testing for Cancer Sales by Country (2023-2028) & (K Units)
Table 56. North America Biomarker Testing for Cancer Revenue by Country (2017-2022) & (US$ Million)
Table 57. North America Biomarker Testing for Cancer Revenue by Country (2023-2028) & (US$ Million)
Table 58. Europe Biomarker Testing for Cancer Sales by Type (2017-2022) & (K Units)
Table 59. Europe Biomarker Testing for Cancer Sales by Type (2023-2028) & (K Units)
Table 60. Europe Biomarker Testing for Cancer Revenue by Type (2017-2022) & (US$ Million)
Table 61. Europe Biomarker Testing for Cancer Revenue by Type (2023-2028) & (US$ Million)
Table 62. Europe Biomarker Testing for Cancer Sales by Application (2017-2022) & (K Units)
Table 63. Europe Biomarker Testing for Cancer Sales by Application (2023-2028) & (K Units)
Table 64. Europe Biomarker Testing for Cancer Revenue by Application (2017-2022) & (US$ Million)
Table 65. Europe Biomarker Testing for Cancer Revenue by Application (2023-2028) & (US$ Million)
Table 66. Europe Biomarker Testing for Cancer Sales by Country (2017-2022) & (K Units)
Table 67. Europe Biomarker Testing for Cancer Sales by Country (2023-2028) & (K Units)
Table 68. Europe Biomarker Testing for Cancer Revenue by Country (2017-2022) & (US$ Million)
Table 69. Europe Biomarker Testing for Cancer Revenue by Country (2023-2028) & (US$ Million)
Table 70. Asia Pacific Biomarker Testing for Cancer Sales by Type (2017-2022) & (K Units)
Table 71. Asia Pacific Biomarker Testing for Cancer Sales by Type (2023-2028) & (K Units)
Table 72. Asia Pacific Biomarker Testing for Cancer Revenue by Type (2017-2022) & (US$ Million)
Table 73. Asia Pacific Biomarker Testing for Cancer Revenue by Type (2023-2028) & (US$ Million)
Table 74. Asia Pacific Biomarker Testing for Cancer Sales by Application (2017-2022) & (K Units)
Table 75. Asia Pacific Biomarker Testing for Cancer Sales by Application (2023-2028) & (K Units)
Table 76. Asia Pacific Biomarker Testing for Cancer Revenue by Application (2017-2022) & (US$ Million)
Table 77. Asia Pacific Biomarker Testing for Cancer Revenue by Application (2023-2028) & (US$ Million)
Table 78. Asia Pacific Biomarker Testing for Cancer Sales by Region (2017-2022) & (K Units)
Table 79. Asia Pacific Biomarker Testing for Cancer Sales by Region (2023-2028) & (K Units)
Table 80. Asia Pacific Biomarker Testing for Cancer Revenue by Region (2017-2022) & (US$ Million)
Table 81. Asia Pacific Biomarker Testing for Cancer Revenue by Region (2023-2028) & (US$ Million)
Table 82. Latin America Biomarker Testing for Cancer Sales by Type (2017-2022) & (K Units)
Table 83. Latin America Biomarker Testing for Cancer Sales by Type (2023-2028) & (K Units)
Table 84. Latin America Biomarker Testing for Cancer Revenue by Type (2017-2022) & (US$ Million)
Table 85. Latin America Biomarker Testing for Cancer Revenue by Type (2023-2028) & (US$ Million)
Table 86. Latin America Biomarker Testing for Cancer Sales by Application (2017-2022) & (K Units)
Table 87. Latin America Biomarker Testing for Cancer Sales by Application (2023-2028) & (K Units)
Table 88. Latin America Biomarker Testing for Cancer Revenue by Application (2017-2022) & (US$ Million)
Table 89. Latin America Biomarker Testing for Cancer Revenue by Application (2023-2028) & (US$ Million)
Table 90. Latin America Biomarker Testing for Cancer Sales by Country (2017-2022) & (K Units)
Table 91. Latin America Biomarker Testing for Cancer Sales by Country (2023-2028) & (K Units)
Table 92. Latin America Biomarker Testing for Cancer Revenue by Country (2017-2022) & (US$ Million)
Table 93. Latin America Biomarker Testing for Cancer Revenue by Country (2023-2028) & (US$ Million)
Table 94. Middle East and Africa Biomarker Testing for Cancer Sales by Type (2017-2022) & (K Units)
Table 95. Middle East and Africa Biomarker Testing for Cancer Sales by Type (2023-2028) & (K Units)
Table 96. Middle East and Africa Biomarker Testing for Cancer Revenue by Type (2017-2022) & (US$ Million)
Table 97. Middle East and Africa Biomarker Testing for Cancer Revenue by Type (2023-2028) & (US$ Million)
Table 98. Middle East and Africa Biomarker Testing for Cancer Sales by Application (2017-2022) & (K Units)
Table 99. Middle East and Africa Biomarker Testing for Cancer Sales by Application (2023-2028) & (K Units)
Table 100. Middle East and Africa Biomarker Testing for Cancer Revenue by Application (2017-2022) & (US$ Million)
Table 101. Middle East and Africa Biomarker Testing for Cancer Revenue by Application (2023-2028) & (US$ Million)
Table 102. Middle East and Africa Biomarker Testing for Cancer Sales by Country (2017-2022) & (K Units)
Table 103. Middle East and Africa Biomarker Testing for Cancer Sales by Country (2023-2028) & (K Units)
Table 104. Middle East and Africa Biomarker Testing for Cancer Revenue by Country (2017-2022) & (US$ Million)
Table 105. Middle East and Africa Biomarker Testing for Cancer Revenue by Country (2023-2028) & (US$ Million)
Table 106. F. Hoffmann-L A Roche Corporation Information
Table 107. F. Hoffmann-L A Roche Description and Major Businesses
Table 108. F. Hoffmann-L A Roche Biomarker Testing for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 109. F. Hoffmann-L A Roche Biomarker Testing for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
Table 110. F. Hoffmann-L A Roche Recent Developments
Table 111. Thermo Fisher Scientific Corporation Information
Table 112. Thermo Fisher Scientific Description and Major Businesses
Table 113. Thermo Fisher Scientific Biomarker Testing for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 114. Thermo Fisher Scientific Biomarker Testing for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
Table 115. Thermo Fisher Scientific Recent Developments
Table 116. Qiagen N.V. Corporation Information
Table 117. Qiagen N.V. Description and Major Businesses
Table 118. Qiagen N.V. Biomarker Testing for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 119. Qiagen N.V. Biomarker Testing for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
Table 120. Qiagen N.V. Recent Developments
Table 121. Bio-Rad L aboratories Corporation Information
Table 122. Bio-Rad L aboratories Description and Major Businesses
Table 123. Bio-Rad L aboratories Biomarker Testing for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 124. Bio-Rad L aboratories Biomarker Testing for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
Table 125. Bio-Rad L aboratories Recent Developments
Table 126. llumina Corporation Information
Table 127. llumina Description and Major Businesses
Table 128. llumina Biomarker Testing for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 129. llumina Biomarker Testing for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
Table 130. llumina Recent Developments
Table 131. Key Raw Materials Lists
Table 132. Raw Materials Key Suppliers Lists
Table 133. Biomarker Testing for Cancer Distributors List
Table 134. Biomarker Testing for Cancer Customers List
Table 135. Biomarker Testing for Cancer Market Trends
Table 136. Biomarker Testing for Cancer Market Drivers
Table 137. Biomarker Testing for Cancer Market Challenges
Table 138. Biomarker Testing for Cancer Market Restraints
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
List of Figures
Figure 1. Biomarker Testing for Cancer Product Picture
Figure 3. Global Biomarker Testing for Cancer Market Share by Type in 2021 & 2028
Figure 3. Protein Biomarkers Product Picture
Figure 4. Genetic Biomarkers Product Picture
Figure 5. Others Product Picture
Figure 6. Global Biomarker Testing for Cancer Market Share by Application in 2021 & 2028
Figure 7. Diagnostics
Figure 8. Research & Development
Figure 9. Prognostics
Figure 10. Risk Assessment
Figure 11. Others
Figure 12. Biomarker Testing for Cancer Report Years Considered
Figure 13. Global Biomarker Testing for Cancer Sales 2017-2028 (K Units)
Figure 14. Global Biomarker Testing for Cancer Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 15. Global Biomarker Testing for Cancer Revenue 2017-2028 (US$ Million)
Figure 16. Global Biomarker Testing for Cancer Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 17. Global Biomarker Testing for Cancer Sales Market Share by Region (2017-2022)
Figure 18. Global Biomarker Testing for Cancer Sales Market Share by Region (2023-2028)
Figure 19. North America Biomarker Testing for Cancer Sales YoY (2017-2028) & (K Units)
Figure 20. North America Biomarker Testing for Cancer Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Europe Biomarker Testing for Cancer Sales YoY (2017-2028) & (K Units)
Figure 22. Europe Biomarker Testing for Cancer Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Asia-Pacific Biomarker Testing for Cancer Sales YoY (2017-2028) & (K Units)
Figure 24. Asia-Pacific Biomarker Testing for Cancer Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Latin America Biomarker Testing for Cancer Sales YoY (2017-2028) & (K Units)
Figure 26. Latin America Biomarker Testing for Cancer Revenue YoY (2017-2028) & (US$ Million)
Figure 27. Middle East & Africa Biomarker Testing for Cancer Sales YoY (2017-2028) & (K Units)
Figure 28. Middle East & Africa Biomarker Testing for Cancer Revenue YoY (2017-2028) & (US$ Million)
Figure 29. The Biomarker Testing for Cancer Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 30. The Top 5 and 10 Largest Manufacturers of Biomarker Testing for Cancer in the World: Market Share by Biomarker Testing for Cancer Revenue in 2021
Figure 31. Global Biomarker Testing for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 32. Global Biomarker Testing for Cancer Sales Market Share by Type (2017-2028)
Figure 33. Global Biomarker Testing for Cancer Revenue Market Share by Type (2017-2028)
Figure 34. Global Biomarker Testing for Cancer Sales Market Share by Application (2017-2028)
Figure 35. Global Biomarker Testing for Cancer Revenue Market Share by Application (2017-2028)
Figure 36. North America Biomarker Testing for Cancer Sales Market Share by Type (2017-2028)
Figure 37. North America Biomarker Testing for Cancer Revenue Market Share by Type (2017-2028)
Figure 38. North America Biomarker Testing for Cancer Sales Market Share by Application (2017-2028)
Figure 39. North America Biomarker Testing for Cancer Revenue Market Share by Application (2017-2028)
Figure 40. North America Biomarker Testing for Cancer Sales Share by Country (2017-2028)
Figure 41. North America Biomarker Testing for Cancer Revenue Share by Country (2017-2028)
Figure 42. United States Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 43. Canada Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 44. Europe Biomarker Testing for Cancer Sales Market Share by Type (2017-2028)
Figure 45. Europe Biomarker Testing for Cancer Revenue Market Share by Type (2017-2028)
Figure 46. Europe Biomarker Testing for Cancer Sales Market Share by Application (2017-2028)
Figure 47. Europe Biomarker Testing for Cancer Revenue Market Share by Application (2017-2028)
Figure 48. Europe Biomarker Testing for Cancer Sales Share by Country (2017-2028)
Figure 49. Europe Biomarker Testing for Cancer Revenue Share by Country (2017-2028)
Figure 50. Germany Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 51. France Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 52. U.K. Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 53. Italy Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 54. Russia Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 55. Asia Pacific Biomarker Testing for Cancer Sales Market Share by Type (2017-2028)
Figure 56. Asia Pacific Biomarker Testing for Cancer Revenue Market Share by Type (2017-2028)
Figure 57. Asia Pacific Biomarker Testing for Cancer Sales Market Share by Application (2017-2028)
Figure 58. Asia Pacific Biomarker Testing for Cancer Revenue Market Share by Application (2017-2028)
Figure 59. Asia Pacific Biomarker Testing for Cancer Sales Share by Region (2017-2028)
Figure 60. Asia Pacific Biomarker Testing for Cancer Revenue Share by Region (2017-2028)
Figure 61. China Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 62. Japan Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 63. South Korea Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 64. India Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 65. Australia Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 66. China Taiwan Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 67. Indonesia Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 68. Thailand Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 69. Malaysia Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 70. Latin America Biomarker Testing for Cancer Sales Market Share by Type (2017-2028)
Figure 71. Latin America Biomarker Testing for Cancer Revenue Market Share by Type (2017-2028)
Figure 72. Latin America Biomarker Testing for Cancer Sales Market Share by Application (2017-2028)
Figure 73. Latin America Biomarker Testing for Cancer Revenue Market Share by Application (2017-2028)
Figure 74. Latin America Biomarker Testing for Cancer Sales Share by Country (2017-2028)
Figure 75. Latin America Biomarker Testing for Cancer Revenue Share by Country (2017-2028)
Figure 76. Mexico Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 77. Brazil Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 78. Argentina Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 79. Colombia Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 80. Middle East and Africa Biomarker Testing for Cancer Sales Market Share by Type (2017-2028)
Figure 81. Middle East and Africa Biomarker Testing for Cancer Revenue Market Share by Type (2017-2028)
Figure 82. Middle East and Africa Biomarker Testing for Cancer Sales Market Share by Application (2017-2028)
Figure 83. Middle East and Africa Biomarker Testing for Cancer Revenue Market Share by Application (2017-2028)
Figure 84. Middle East and Africa Biomarker Testing for Cancer Sales Share by Country (2017-2028)
Figure 85. Middle East and Africa Biomarker Testing for Cancer Revenue Share by Country (2017-2028)
Figure 86. Turkey Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 87. Saudi Arabia Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 88. UAE Biomarker Testing for Cancer Revenue (2017-2028) & (US$ Million)
Figure 89. Biomarker Testing for Cancer Value Chain
Figure 90. Biomarker Testing for Cancer Production Process
Figure 91. Channels of Distribution
Figure 92. Distributors Profiles
Figure 93. Bottom-up and Top-down Approaches for This Report
Figure 94. Data Triangulation
Figure 95. Key Executives Interviewed

★調査レポート[がん向けバイオマーカー検査の世界市場インサイト・予測（～2028年）] (コード：QY22JLX09341)販売に関する免責事項を必ずご確認ください。

★調査レポート[がん向けバイオマーカー検査の世界市場インサイト・予測（～2028年）]についてメールでお問い合わせ

MarketReport.jp

がん向けバイオマーカー検査の世界市場インサイト・予測（～2028年）

市場調査レポート・産業資料総合販売サイト www.MarketReport.jp

市場調査レポート・産業資料 総合販売サイト www.MarketReport.jp

市場調査レポート・産業資料総合販売サイト www.MarketReport.jp